13 results about "Wnt antagonists" patented technology

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

Disclosed herein include methods, compositions, and kits suitable for use in vaccination. Provided are nucleic acid compositions (e.g., mRNA vaccines, DNA vaccines) comprising a first nucleic acid composition comprising a polynucleotide encoding one or more enveloped nanoparticle (ENP) proteins and a second nucleic acid composition comprising a polynucleotide comprising or encoding a tetherin inhibitor. An ENP protein can comprise an endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD). Recruitment of one or more ESCRT proteins results in secretion of enveloped nanoparticles (ENPs) from a cell in which an ENP protein expressed. The tetherin inhibitor can increase ENP production from the cell relative to, e.g., a cell that does not express the tetherin inhibitor. There are also provided populations of ENPs in some embodiments.

The invention relates to the technical field of biological medicines, in particular to a method for inducing neural stem cells to differentiate into dopaminergic neurons by a small molecule compound. A magnetic mesoporous silica-phase change liposome composite system is constructed, wherein the surface of a three-dimensional porous bioglass substrate is modified with bifunctional peptide, and a glycogen synthase kinase inhibitor, a transmembrane protease inhibitor and a bone morphogenetic protein receptor antagonist are loaded on the three-dimensional porous bioglass substrate. A response mechanism of a photosensitive cyclic adenylate analogue and a dopamine synthesis precursor is activated through blue light pulses, and finally targeted sorting is completed by a fluorescent tracing substrate, so that a high-purity functional dopaminergic neuron population is obtained. Through physical microenvironment optimization, chemical signal channel regulation and control and multi-dimensional integration of a light-operated maturation mechanism, efficient and controllable differentiation of neural stem cells to dopaminergic neurons is realized, and a standardized preparation scheme is provided for Parkinson's disease cell therapy.

The invention discloses an IL-11 long-acting protein antagonist compound and application thereof, according to the sequence characteristics (SEQ ID NO.1) and receptor binding characteristics of human IL11 mutein, Cys mutation is introduced at a specific site by using site-specific mutagenesis, and an activity maintenance mutant is screened by means of cell activity. By utilizing a chemical reaction, fatty acids with different lengths of side chains C16-C22 are introduced into a Cys side chain for modification, and a long-acting product with kept activity is screened by virtue of cell activity again.

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.

The invention relates to a nucleic acid aptamer for specifically recognizing fibroblast growth factor 10 (FGF10) protein as well as a screening method and application of the nucleic acid aptamer. The nucleic acid aptamer is at least one of FAS-1, FAS-4, FAS-9, FAS-10 and FAS-12, and is obtained by screening through a magnetic bead-SELEX (systematic evolution of ligands by exponential enrichment) technology. The aptamer can be combined with FGF10 protein with high affinity, the equilibrium dissociation constant (Kd) of the aptamer is within the range of 5-20 nM, and the aptamer has good recognition specificity. By means of the excellent performance, the nucleic acid aptamer has wide application prospects in construction of an efficient detection method of the FGF10 protein and research and development of an FGF10 antagonist.

The application discloses a genetically engineered probiotic preparation and its use in tumor immunotherapy. The genetically engineered probiotic contains an expression cassette regulated by an inflammation-responsive promoter, which can encode a novel trifunctional fusion protein. The fusion protein contains a secretion signal peptide, a human IL-1 receptor antagonist, a flexible linker, an anti-human GM-CSF nanobody, a second flexible linker, and an anti-human PD-L1 nanobody in sequence. In vitro experiments confirm that the fusion protein has complete biological activity, can simultaneously neutralize GM-CSF, block PD-1 / PD-L1 binding, and inhibit the IL-1 signaling pathway. Animal experiments show that oral administration of the probiotic can significantly enhance the anti-tumor efficacy of CAR-T cells, effectively prevent and alleviate cytokine release syndrome, and provide a safe and effective adjuvant therapy strategy for CAR-T therapy.

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

This invention discloses the application of PACAP peptides as plant immunomodulators, belonging to the field of plant immunology technology. This invention is the first to apply PACAP to a plant system, discovering that it can act as a novel plant immunomodulator to regulate plant immune responses, thereby enhancing plant resistance to pathogenic microorganisms. Experimental results show that PACAP can rapidly induce intracellular calcium ion influx in Arabidopsis thaliana cells, activate the MAPK signaling pathway, and upregulate the expression of early immune marker genes such as FRK1. Furthermore, PACAP treatment significantly improves plant resistance to pathogens such as *Pseudomonas syringae* and *Ralstonia solanacearum*. This invention also confirms that not only does the full-length PACAP (1-38) possess plant immune-promoting activity, but its N-terminal truncated peptide (1-27) and receptor antagonist fragment (6-38) also have plant immune-inducing functions. This invention provides a new technical solution for the development of plant immune inducers.

The invention belongs to the technical field of microorganisms, and discloses an NTase protein, a screening method thereof and application of the NTase protein in preparation of an anti-phage signal system antagonist and / or an antibacterial preparation. The NTase protein provided by the invention specifically comprises an amino acid fragment with a sequence as shown in SEQ ID NO: 1 or a variant fragment with at least 70% sequence identity with the sequence as shown in SEQ ID NO: 1, the NTase protein has an excellent antagonistic effect on a CBASS system of prokaryotes, and the infection efficiency of viruses on prokaryotic cells can be improved by inhibiting the CBASS system; therefore, a better antibacterial effect is achieved, and the compound has a very excellent application prospect in research and development of novel antibacterial drugs.

The invention relates to a heterocyclic compound with hedgehog pathway antagonist activity, in particular to a compound with a structure shown in a formula A or pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer and prodrug thereof. The compound can effectively block a Shh signal pathway, and meanwhile, can down-regulate expression of pulmonary fibrosis related protein alpha-SMA protein; the lung fibrosis lesion process can be obviously inhibited.